Galapagos NV (NASDAQ:GLPG) Receives $31.00 Consensus Target Price from Analysts

Galapagos NV (NASDAQ:GLPG) has earned an average recommendation of “Reduce” from the five research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $31.00.

Several analysts recently commented on GLPG shares. Raymond James cut shares of Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. Leerink Partners started coverage on shares of Galapagos in a report on Monday, September 9th. They set a “market perform” rating and a $24.00 price target for the company. Finally, Leerink Partnrs upgraded shares of Galapagos to a “hold” rating in a report on Monday, September 9th.

Institutional Trading of Galapagos

A number of institutional investors have recently added to or reduced their stakes in GLPG. Vestal Point Capital LP acquired a new stake in Galapagos in the fourth quarter valued at approximately $5,284,000. Stonepine Capital Management LLC lifted its stake in Galapagos by 23.2% in the second quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company’s stock valued at $12,018,000 after acquiring an additional 91,366 shares during the last quarter. DME Capital Management LP lifted its stake in Galapagos by 46.9% in the second quarter. DME Capital Management LP now owns 234,828 shares of the biotechnology company’s stock valued at $5,819,000 after acquiring an additional 75,000 shares during the last quarter. Wellington Management Group LLP lifted its stake in Galapagos by 3.9% in the fourth quarter. Wellington Management Group LLP now owns 495,217 shares of the biotechnology company’s stock valued at $20,131,000 after acquiring an additional 18,552 shares during the last quarter. Finally, Creative Planning acquired a new stake in Galapagos in the second quarter valued at approximately $456,000. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Galapagos Trading Up 2.0 %

Shares of GLPG opened at $29.81 on Friday. The company has a 50-day moving average of $27.96 and a two-hundred day moving average of $27.99. Galapagos has a one year low of $24.16 and a one year high of $42.46.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.